Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses current treatment approaches in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and how tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape of this disease. Dr Luskin also highlights some unanswered questions in this space, and further discusses a Phase I clinical trial which is evaluating the combination of dasatinib and asciminib in patients with Ph+ ALL. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.